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Abstract 
After 230 years of use, digitalis remains an important and useful therapy for patients with atrial 
fibrillation, heart failure and the 30-50 % of patients with both conditions.  Although the 
combination of positive inotropic activity with negative chronotropic effects have been shown to 
reduce hospital admissions in heart failure, there is a distinct lack of robust trial data, particularly in 
patients with atrial fibrillation.  We recently performed a comprehensive meta-analysis of all 
digoxin studies and demonstrated a neutral effect on mortality.  This contradicts prior observational 
data that overlooks the fact that digitalis is usually given as second-line therapy to the sickest 
patients.  Use of these agents in clinical practice should take account of appropriate dose, serum 
concentration, drug interactions and potential side effects.  The aim of this review is to evaluate the 
evidence base for cardiac glycosides and provide a pragmatic guide to their advantages and 
disadvantages. 
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Abbreviations 
ACEI   Angiotensin Converting Enzyme Inhibitor 
AF   Atrial Fibrillation 
AHA   American Heart Association 
ARB   Angiotensin 2 Receptor Blocker 
AVN   Atrioventricular Node 
CI   Confidence Interval 
CKD   Chronic Kidney Disease 
CO   Cardiac Output 
CRT   Cardiac Resynchronisation Therapy 
HFpEF  Heart Failure with preserved Ejection Fraction 
HFrEF   Heart Failure with reduced Ejection Fraction 
HR   Hazard Ratio 
LVEF   Left Ventricular Ejection Fraction 
NYHA   New York Heart Association 
OR   Odds Radio 
PCWP   Pulmonary Capillary Wedge Pressure 
RCT   Randomised Controlled Trial 
RR   Relative Risk 
SDC   Serum Digoxin Concentration 
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Introduction 
Sir William Withering first described the use of the foxglove plant, Digitalis purpurea, for heart 
failure (HF) in Birmingham, UK in 1785 (1).  Over two centuries later, cardiac glycosides are still 
widely used as a positive inotrope in HF and for its negative chronotropic activity in atrial 
fibrillation (AF).  A small number of randomised controlled trials (RCTs) have provided evidence 
to support the use of digoxin in patients with HF due to reduced ejection fraction (HFrEF) (2).  
Notably the Digoxin Investigators’ Group (DIG) trial showed that digoxin improved symptoms and 
reduced hospitalisation rates without any impact on all-cause mortality (3,4).  Following the 
availability of therapies providing prognostic benefit in HFrEF (including angiotensin converting 
enzyme inhibitors, beta-blockers, aldosterone antagonists and cardiac resynchronisation therapy), 
prescription rates of digoxin have fallen substantially (5,6).  However, there were high rates of 
concomitant digoxin use in the trials of these agents.  For example, in the major beta-blocker RCTs, 
an average of 58% of participants were on digoxin at baseline (range 9% to 92%) (7). 
  
The publication of numerous observational studies reporting increased mortality with digoxin have 
intensified clinical concern.  In the OPTIMIZE-HF registry only 30% of patients with HFrEF were 
prescribed digoxin prior to hospitalisation.  By discharge, digoxin was only prescribed in a further 
8%, despite the presence of on-going symptoms on guideline-recommended therapy (8).  However, 
observational trials of digoxin are flawed by unavoidable prescription bias, with clear disparity in 
baseline characteristics between those patients given digoxin and the control groups (typically no 
therapy) (2).  Furthermore, post-hoc analyses of the DIG trial have demonstrated a decrease in 
mortality amongst those with low serum digoxin levels (3,9).   
 
In this article, we address the evidence for digoxin in HF and AF populations, and highlight the 
advantages and limitations which guide clinical decisions about the use of this therapy.  
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Mechanism of action 
Digitalis has three key pharmacological mechanisms of action; haemodynamic, neurohormonal and 
electrophysiological (Figure 1).  Firstly, digitalis reversibly inhibits the membrane bound alpha 
subunits of the sodium-potassium ATPase pump in cardiomyocytes (10).  The resulting increased 
intracellular sodium concentration promotes activity of the sodium calcium exchanger, increasing 
intracellular calcium concentration.  Greater interaction between the myocardial contractile proteins 
improves the force of contraction leading to a global increase in left ventricular systolic function 
(11).  When intravenous digoxin is administered acutely in patients with HFrEF in sinus rhythm, 
there is a short-term improvement in cardiac output, left ventricular ejection fraction (LVEF), stroke 
index, pulmonary capillary wedge pressure, exercise tolerance and peak VO2 (12,13).  Secondly, 
digitalis induces vagal activation leading to a shift in autonomic balance towards parasympathetic 
dominance.  The pathophysiology of HF includes an initial compensatory and later detrimental 
neurohormonal activation.  Digoxin modulates these neurohormonal abnormalities, reducing plasma 
norepinephrine.  The mechanism for this direct anti-sympathetic activity has not been fully 
elucidated, but is likely to reflect attenuation and sensitisation of the pathologically augmented 
baroreflex in HF patients with raised filling pressures (14,15).  
Finally, inhibition of the sodium-potassium ATPase by digoxin slows the heart rate.  Whether heart 
rate is a determinant of prognosis in HF patients or simply an indicator for increased sympathetic 
tone is contentious.  However, ivabradine, a drug that acts solely to reduce heart rate (without 
evidence for substantial modulation of neurohormonal response), has been shown to improve 
prognosis in HF patients with sinus rhythm (16).  Digitalis exerts a parasympathomimetic action on 
the sinoatrial node and atrioventricular node (AVN), slowing their conduction and increasing the 
refractory period.  Importantly during exercise, or whenever there is increased sympathetic activity, 
the rate controlling effects of digitalis are overcome.  The sodium-potassium ATPase is targeted by 
a variety of endogenous and exogenous cardiac glycosides and cardiotonic steroids, with increasing 
titres of the latter seen in disease states (17).  Differing levels of endogenous cardiotonic steroids 
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may partly explain the varied susceptibility to digoxin toxicity, including competition for molecular 
targets and conformational changes that lead to synergism or antagonism (18,19). 
 
The collective properties of digitalis make it unique in being able to positively influence cardiac 
inotropy, whilst simultaneously constraining the chronotropic action of the heart.  However, the 
digoxin plasma level determines which of these mechanisms predominates; although 
haemodynamic effects are very limited at low levels, significant reductions in norepinephrine are 
still observed (15).  
 
Around 80% of oral digoxin is absorbed, principally in the proximal small intestine, and then 20-
30% is bound to serum albumin.  Digoxin undergoes widespread dissemination into the tissues, 
particularly the myocardium, kidneys and skeletal muscle.  The half-life in healthy individuals is 
26-45 hours, with renal excretion being the principle route of elimination (20). 
 
Evaluating the evidence base 
Digoxin is particularly prone to prescription bias, as clinicians tend to use digoxin in sicker patients.  
Since digoxin is not recommended as first-line therapy for either AF or HF, it is usually only 
prescribed when physicians recognise clinical deterioration in patients already receiving therapy.  
Thus, the prescribing of digoxin is prone to being influenced by the likelihood of death, creating a 
scenario of “confounding by indication.”  This results in profound differences in baseline 
characteristics between digoxin and control groups in observational studies, distorting the analysis 
of clinical outcomes (Figure 2) (2).  Although statistical adjustment for known confounders is 
possible, important residual confounders can be unknown or masked.  When treatment and control 
groups differ vastly in characteristics, reliable effect estimates are not possible, even for 
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sophisticated techniques such as propensity-score matching (21).  This reinforces the need for well-
designed RCTs to guide decisions on clinical therapy. 
 
Evidence underpinning the use of digitalis 
Heart failure 
Heart failure is a common and costly condition with increasing prevalence and high mortality (22).  
In HFrEF, there are clinical trials that have examined the efficacy of digoxin compared to placebo, 
vasodilators, and other inotropes.   
The DIG trial is currently the largest and most rigorous assessment of digoxin in HFrEF patients 
with sinus rhythm, including 6,800 participants with LVEF ≤45% randomised to digoxin or 
placebo.  All patients were treated with ACE inhibitors and diuretics and the mean digoxin dose 
was 250 micrograms (3).  After 37 months follow-up, there was no difference in all-cause mortality 
between digoxin and placebo groups (34.8% vs 35.1%; risk ratio 0.99, 95% CI 0.91-1.07), but 
digoxin led to a small but significant reduction in all-cause hospitalisation (64.3% vs 67.1%, risk 
ratio 0.92, 95% CI 0.87-0.98),  These findings have been replicated in other RCTs, as demonstrated 
by a comprehensive meta-analysis (Figure 3), which also exposes how observational data can be 
misleading due to marked differences in patients receiving digoxin and control therapy (2). 
Three placebo-controlled trials compared the effect of digoxin withdrawal with continuation in 
patients with stable HFrEF (23-25).  All showed that withdrawal from digoxin leads to a 
deterioration in exercise tolerance, worsening HF and a reduction in ejection fraction (24-26).  
Pooled analysis demonstrated that triple therapy with digoxin, ACE inhibitors and diuretic reduced 
the risk of worsening HF, with digoxin contributing to a significant cost reduction (27,28).  A meta-
analysis of studies stopping HF medications confirmed that digoxin withdrawal increased HF 
hospitalisation (RR 1.30, 95% CI 1.16-1.46) but had no impact on all-cause mortality (RR 1.00, 
95% CI 0.90-1.12) (29). 
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European and American guidelines indicate that digoxin is beneficial in patients with HFrEF to 
reduce HF hospitalisations (Table 1) (22,30).  Digoxin is recommended for persistent symptoms 
despite optimal therapy or as an alternative or adjunct to reduce hospitalisation.  Since digoxin 
provides symptomatic relief but no survival benefit, it is not indicated in asymptomatic patients.  
Digoxin is rarely useful for acute stabilisation of symptomatic patients with decompensated HF, 
who should be managed with diuretics, nitrate therapy and possibly inotropes.  In patients already 
taking digoxin, it is advisable to avoid withdrawal, and digoxin should be continued throughout 
introduction of ACE inhibitors and other first-line HF agents.   
 
Patients with heart failure with preserved ejection (HFpEF) have received less attention.  Around 
half of patients with heart failure have HFpEF, but as yet, there are no therapies known to reduce 
mortality.  This also applies to digoxin, as shown by the ancillary DIG trial, which included 988 
patients with HFpEF (LVEF >45%) and sinus rhythm.  Digoxin was associated with a non-
significant trend towards reduction in HF hospitalisation (hazard ratio [HR] 0.79, 95% CI 0.59-
1.04), but this was counterbalanced by a trend towards increased hospitalisations for unstable 
angina (HR 1.37, 95% CI 0.99-1.91) (4).  Further studies on concomitant HFpEF and AF are 
urgently needed to better inform clinical practice. 
 
Atrial fibrillation 
Atrial fibrillation is the most common arrhythmia, with rapidly increasing prevalence (31).  
Management involves prevention of stroke and systemic embolization, restoring sinus rhythm in 
selected patients and control of heart rate.  Rate control is achieved using drugs that slow 
conduction across the AVN, such as beta-blockers, non-dihydropyridine calcium channel blockers 
(diltiazem or verapamil), and digoxin.  Unfortunately, there are limited comparative data available 
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to choose appropriate therapy for individual patients (32,33).  At present there are no randomised, 
head-to-head studies of digoxin in patients with AF. 
 
As previously mentioned, observational data are confounded and not suitable to make clinical 
decisions on treatments such as digoxin, which is typically given to the sickest individuals (2).  This 
has not stopped researchers from attempting to meta-analyse observational data, which 
unsurprisingly show that digoxin is associated with increased mortality in AF patients (Table 2) 
(2,29,34-40).  These findings are incongruous with data in patients with HFrEF plus AF (see below) 
and the reduction in hospital admissions in HF.  Remarkably, three different post-hoc analyses of 
the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) dataset 
demonstrated divergent findings for digoxin, highlighting the problems of using observational data 
(41-43).  Until further RCTs are available, digoxin remains an important contribution to achieving 
rate control in AF patients.  Clinical guidelines for AF suggest digoxin as second-line therapy, after 
beta-blockers, verapamil and diltiazem (Table 1) (44-46).   
 
Concomitant heart failure and atrial fibrillation 
Heart failure and AF share pathophysiology, increasing the risk of the other condition, and hence 
frequently co-exist in clinical practice (47).  Irrespective of which comes first, this combination 
considerably worsens prognosis (48).  Although concomitant HFrEF with AF is associated with 
higher all-cause mortality than HFpEF with AF, patients have similar rates of stroke and hospital 
admission (49).   
 
In general, patients with HF and AF have been underrepresented in clinical trials and management 
of these patients has typically followed that of HF, overlooking the impact that AF has on the 
efficacy of available therapies and interventions.  For example, beta-blockers were shown to have 
no significant effect on mortality or hospitalisation in HFrEF patients with concomitant AF in an 
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individual patient data meta-analysis of all major placebo-controlled RCTs (7).  The adjusted HR 
for death was 0.97 (95% CI 0.83-1.14), markedly different to the benefit seen in patients with sinus 
rhythm (HR 0.73, 95% CI 0.67-0.80), and with a highly significant p-value for interaction of 
baseline heart rhythm (p=0.002).  This has led to questions about what alternatives clinicians have 
available for rate control, particularly as verapamil and diltiazem have negatively inotropic effects 
on the failing myocardium and can potentially increase adverse outcomes (50).   
 
Unfortunately, trial evidence to clearly define the place of digoxin in the clinical management of 
these patients is limited.  Only a handful of studies have assessed the impact of digoxin on mortality 
in patients with HF and AF, all of which are observational (51-54).  The HR for all-cause mortality 
with digoxin compared to control in meta-analysis of two studies with standard baseline adjustment 
was 0.90 (95% CI 0.70-1.16) and 1.08 (95% CI 0.93-1.26) in two studies with propensity matching 
(2).  Therefore, although based on suboptimal data, there is no suggestion that digoxin increases 
mortality in patients with concomitant HF and AF, and in fact we observed similar effects to that 
seen in HF patients without AF.  In a large prospective registry of AF patients in the United States, 
there was no increase in mortality or hospitalisation in patients using digoxin, with or without HF 
(55).  A single RCT of 47 patients has examined digoxin and beta-blockers in patients with HFrEF 
and persistent AF (56).  Double-blinded withdrawal of digoxin led to a decline in LVEF and 
increase in BNP, although the size of the trial limits further conclusions.  Relevant guidelines are 
presented in Table 1 and data from other observational meta-analyses are summarised in Table 2.    
Practical use of digoxin 
Cardiac glycosides are one of the more challenging cardiovascular therapies to prescribe and 
administer.  In this section, we describe some of the practical considerations involved, including 
dose, serum digoxin concentration (SDC), drug interactions and adverse treatment effects. 
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1. Dose and serum concentrations 
The dose of cardiac glycoside required (digoxin or digitoxin) depends on the clinical indication.  
For example, acute heart rate control requires rapid loading with higher doses via the intravenous 
route, whereas control of HF symptoms can be achieved with smaller doses and a longer time to 
steady-state through the oral route (Table 3).   
 
Although digoxin dose correlates well with serum concentration, in patients with low muscle mass 
or renal impairment the serum concentration relative to the dose will be proportionally increased.  A 
quantitative SDC can be measured in most hospitals using a standard radioimmunoassay.  However, 
SDC monitoring is highly impractical, with samples required 8-12 hours post-dose to ensure 
adequate distribution.  Blood collected prior to this will show a falsely elevated SDC.  Since it takes 
time for digoxin to achieve steady state, SDC should not be measured for at least 7 days following 
initiation or alteration in dose.  There is a linear relationship between digoxin dose and SDC, but 
accurately adjusting the dose relies on blood being collected at the correct time, under stable renal 
function.  Even when SDC is in the optimal therapeutic range (0.5-0.9 ng/mL), patients have 
demonstrated clinical signs of toxicity, and conversely asymptomatic patients with “toxic” SDCs 
have been reported (57).  Thus, given the poor correlation between SDC and clinical findings, 
digoxin intoxication remains a clinical diagnosis.  Other concerns include digoxin-like 
immunoreactive substances causing falsely elevated levels in pregnancy, newborns, acromegaly, 
liver disease and renal failure (58).     
 
The association between dose, SDC and clinical outcomes with digoxin is poorly described and 
only post-hoc analyses of limited patient numbers are available.  In the DIG trial, results were 
suggestive of reduced mortality with SDC at one-month of <0.9 ng/mL, and higher mortality with 
SDC ≥1.2 ng/ml (9,59).  In pooled analysis of two smaller RCTs however, there was no association 
between SDC and clinical outcomes (60).  It should be highlighted that these post-hoc analyses of 
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SDC are confounded by the fact that sicker patients may require a higher digoxin dose and higher 
SDC could reflect poorer baseline cardiac or renal function.  However, when appraised together, 
most clinicians would agree that low-dose digoxin therapy, avoiding high or toxic SDC, is the most 
appropriate use of this therapy.  
 
2. Patients with chronic kidney disease 
Renal disease results in prolongation of the half-life of digoxin as 70 to 80% of the drug is 
eliminated unchanged in the urine (with the reminder undergoing hepato-biliary clearance) (61).  
Renal insufficiency also reduces the extravascular volume of distribution of digoxin, elevating SDC 
as mentioned above.  Thus, in patients with underlying renal disease the dose should be modified 
and regular SDC monitoring should be implemented.  Both the initial loading dose and maintenance 
dose must be reduced with the loading dose reduced by 33-50% in severe renal insufficiency, 
including haemodialysis (62).  The initial maintenance dose should be determined by the ideal body 
weight and creatinine clearance and plotted against a normogram (63).  Chronic kidney disease is 
more common in patients most in need of digoxin, are therefore those most vulnerable to toxicity. 
 
3. Drug interactions 
Interactions with digoxin fall into five classes: (i) inhibitors of P-glycoprotein efflux transporters 
increase SDC, such as amiodarone, quinidine, and verapamil; (ii) inducers of P-glycoprotein reduce 
SDC, such as rifampicin and phenytoin; (iii) reduced intestinal absorption, for example 
cholestyramine and antacids ; (iv) electrolyte disturbances which sensitise the heart to the current 
digoxin level, particularly hypokalaemia and hypomagnesaemia; and (v) inhibition of digoxin 
hydrolysis which is responsible for 15% of digoxin metabolism and is observed with macrolides. 
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4. Side effect profile and toxicity 
Side effects of digoxin include an array of clinical effects including gastrointestinal (nausea and 
vomiting), neurological (visual disturbances, disorientation), and cardiac (arrhythmias).  Despite 
this, the DIG trial showed little difference in adverse effects leading to withdrawal compared to 
placebo (3).  Digoxin toxicity is a clinical concern resulting from the narrow therapeutic window 
(0.5 to 0.9 ng/mL).  In toxic doses, digitalis precipitates atrial myocardium impulse initiation, AVN 
block, and an increase in diastolic repolarisation of the AVN (64).  Thus digoxin should be avoided 
in patients with AVN block (unless a permanent pacemaker is in-situ) or Wolff-Parkinson-White 
Syndrome, where digoxin can increase antegrade accessory pathway conduction due to changes in 
the AVN refractory period.  Digoxin can potentially increase the left ventricular outflow tract 
gradient in patients with hypertrophic cardiomyopathy, but can be used safely in those without an 
obstructive phenotype.(65)  Patients who develop clinically significant manifestations of digoxin 
poisoning (i.e. life-threatening arrhythmia, end-organ dysfunction or hyperkalaemia) should be 
treated with digoxin-specific antibody (Fab) fragments (66).  
Summary and future perspectives 
Digitalis is a useful therapy in patients with heart failure and those with atrial fibrillation, but there 
are important practical considerations that complicate its use (Figure 4).  For patients with HFrEF 
who have persistent symptoms despite optimal therapy (e.g. ACEi or ARB, beta blocker) digoxin is 
recommended.  In this population there is a reasonable evidence base to indicate no influence on 
mortality but a reduction in hospital admissions and symptoms.  In patients with AF who require 
rate control, digoxin has yet to be properly investigated in any RCT, with all current 
recommendations based on conflicting observational studies that are of limited value due to 
prescription bias.  When digoxin is indicated, a low-dose approach is suggested to achieve a serum 
digoxin concentration <0.9 ng/mL, although the value of digoxin levels in routine clinical practice 
is unclear.  High serum levels do not improve efficacy and yet increase the risk of toxicity and 
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should be avoided.  Practical use of digoxin is often challenging, as patients are typically elderly 
with renal impairment, polypharmacy and numerous comorbidities. 
 
It has now been 18 years since the last randomised trial of digitalis and there is a clear need for 
further, adequately powered RCTs to answer important clinical questions about the role of digoxin 
in clinical practice.  Two RCTs are currently underway.  The DIGIT-HF trial (Digitoxin to Improve 
Outcomes in Patients with Advanced Systolic Chronic Heart Failure), is comparing digitoxin versus 
placebo in HFrEF (NYHA III-IV and LVEF ≤40%, or NYHA II and LVEF ≤30%) with and 
without AF (67).  The primary outcome is a composite of overall mortality and hospitalisation for 
worsening HF.  The RATE-AF trial (RAte control Therapy Evaluation in Atrial Fibrillation) will 
enrol permanent AF patients with NYHA Class II and above and randomise them to digoxin or 
beta-blockers as first-line rate control.  The primary outcome is patient-reported quality of life and 
secondary outcomes include cardiac function, exercise capacity and biomarkers of cellular and 
clinical effects.  Results are expected in 2019 and will form the basis for a future trial assessing the 
impact of therapy on long-term clinical outcomes in patients with AF (68).  Future work is also 
required to clarify the effect of digoxin concentration and to correlate clinical outcomes with 
haemodynamic, neurohormonal and electrophysiological changes, in order to inform clinicians 
about the good and the bad of digitalis use in the 21st century.  
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Table 1.  Guidelines on digoxin according to population 
Guideline Recommendation Class Level of 
evidence 
Heart Failure 
American College of 
Cardiology/American 
Heart Association 
2013 (30) 
Digoxin can be beneficial in patients with HFrEF, unless contraindicated, to 
decrease hospitalisations for HF. 
IIa B 
European Society of 
Cardiology 2012 (22) 
Digoxin may be considered to reduce the risk of HF hospitalization in patients in 
sinus rhythm with an EF ≤45% who are unable to tolerate a beta-blocker 
(ivabradine is an alternative in patients with a heart rate ≥70 bpm).  
Digoxin may be considered to reduce the risk of HF hospitalization in patients with 
EF ≤45% and persisting symptoms (NYHA II-IV) despite treatment with an 
evidence based dose of beta-blocker, ACE inhibitor (or ARB), and an MRA (or 
ARB). 
IIb 
 
 
IIb 
B 
 
 
B 
Atrial Fibrillation 
American College of 
Cardiology/American 
Heart Association 
(46) 
In patients with pre-excitation and AF, digoxin should not be administered as it 
may increase the ventricular response and may result in ventricular fibrillation. 
III B 
European Society of 
Cardiology 2010 (44) 
Where monotherapy is inadequate for heart rate control, digoxin should be added.   
[In pregnancy] if rate control is indicated, and β-blockers or non-dihydropyridine 
calcium channel antagonists are contraindicated, digoxin may be considered. 
Digoxin is ineffective in converting recent onset AF to sinus rhythm and is not 
recommended. 
When pre-excited AF is present, digoxin is contraindicated. 
I 
IIb  
 
III 
 
III 
B 
C  
 
A 
 
C 
Heart Failure and Atrial Fibrillation 
American College of 
Cardiology/American 
Heart Association 
(46) 
AF guidelines: 
[In AF patients with heart failure] in the absence of pre-excitation, IV digoxin is 
recommended to control heart rate acutely. 
[In AF patients] digoxin is effective to control resting heart rate with HFrEF 
[In AF patients] a combination of digoxin and beta blocker (or a non-
dihydropyridine calcium channel antagonist with HFpEF) is reasonable to control 
resting and exercise heart rate in AF  
Digoxin may be considered to slow a rapid ventricular response with ACS and AF 
associated with severe LV dysfunction and HF or hemodynamic instability 
 
I 
 
I 
IIa 
 
 
IIb 
 
B 
 
C 
B 
 
 
C 
European Society of 
Cardiology (22,44) 
AF guidelines: 
[In AF patients with HF] where monotherapy is inadequate for heart rate control, 
digoxin should be added. 
If an accessory pathway is excluded, digoxin is recommended as an alternative to 
amiodarone to control heart rate in patients with AF and acute systolic HF. 
[In AF patients] digoxin is indicated with heart failure and LV dysfunction, and in 
sedentary (inactive) patients. 
Intravenous administration of digoxin may be considered to slow a rapid ventricular 
response in patients with ACS and AF associated with heart failure. 
 
HF guidelines: 
[In symptomatic HF (NYHA II-IV), LV systolic dysfunction, persistent/permanent 
AF and no evidence of acute decompensation] digoxin is recommended in patients 
unable to tolerate a beta-blocker. 
[In symptomatic HF (NYHA II-IV), LV systolic dysfunction, persistent/permanent 
AF and no evidence of acute decompensation] digoxin is recommended as the 
preferred second drug, in addition to a beta-blocker, to control the ventricular rate 
in patients with an inadequate response to a beta-blocker. 
 
I 
 
I 
 
IIa 
 
IIb 
 
 
 
I 
 
 
I 
 
B 
 
C 
 
C 
 
C 
 
 
 
B 
 
 
B 
ACE, angiotensin converting enzyme; AF, atrial fibrillation; ARB, Angiotensin receptor blocker; 
HF, heart failure; HFrEF, heart failure with reduced ejection fraction; LV, left ventricular; MRA, 
mineralocorticoid receptor antagonist; NYHA , New York Heart Association. 
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Table 2.  Meta-analyses reporting clinical outcomes for digoxin versus control 
Study Studies Sample 
size 
Population Study type Control 
group 
Prospectively 
registered 
Clinical outcomes Digoxin vs control 
(95% CI) 
Comments 
Ziff 
2015 (2) 
52 621,845 All RCT and 
observational 
(analysed 
separately) 
Placebo/no 
treatment 
Yes All-cause mortality: 
  Unadjusted observational 
  Adjusted observational 
  Propensity matched observational  
  RCTs 
Hospitalisation: 
  All-cause  
  Cardiovascular 
  Heart failure related  
 
RR 1.76 (1.57-1.97) 
RR 1.61 (1.31-1.97) 
RR 1.18 (1.09-1.26) 
RR 0.99 (0.93-1.05) 
 
RR 0.92 (0.89-0.95) 
RR 0.92 (0.86–0.97) 
RR 0.89 (0.85-0.93) 
Identified significant 
relationship between 
observed mortality with 
digoxin and study bias. 
Not able to separate AF 
patients due to lack of 
RCTs in this patient 
group. 
Vamos 
2015 (39) 
19 326,426 AF or HF RCT and 
observational  
Placebo/no 
treatment 
No All-cause mortality 
AF group: all-cause mortality 
HF group: all-cause mortality 
HR 1.21 (1.07-1.38) 
HR 1.29 (1.21-1.39) 
HR 1.14 (1.06-1.22) 
Non-systematic with 
arbitrary time period 
studied and inappropriate 
meta-analysis of 
different studies 
including baseline and 
time-varying digoxin 
use. 
Chen  
2015 (35) 
17 408,660 AF Observational No 
treatment 
No All-cause mortality 
AF + HF: all-cause mortality 
AF, no HF: all-cause mortality 
RR 1.22 (1.15-1.30) 
RR 1.14 (1.04-1.24) 
RR 1.36 (1.18-1.56) 
Lack of randomised 
studies.  Heart function 
status not clearly defined 
in the included studies. 
Hood  
2004 (36) 
13 7,896 HF in sinus 
rhythm 
RCT Placebo No All-cause mortality 
HF hospitalisation 
Clinical deterioration 
OR 0.98 (0.89-1.09) 
OR 0.68 (0.61-0.75) 
OR 0.31 (0.21-0.43) 
Restricted to double-
blind placebo-controlled 
RCTs of n ≥20 followed 
for ≥7 weeks. 
Ouyang 
2015 (38) 
11 318,191 AF Observational No 
treatment 
No All-cause mortality 
Propensity analysis: mortality 
AF + HF: all-cause mortality 
AF, no HF: all-cause mortality 
HR 1.21 (1.12-1.30) 
HR 1.17 (1.13-1.22) 
HR 1.15 (1.12-1.17) 
HR 1.18 (1.15-1.21) 
Lack of randomised 
studies.  HF not clearly 
defined in included 
studies. 
Bavishi 
2015 (34) 
10 76,100 AF plus HF Observational No 
treatment 
No All-cause mortality RR 1.15 (1.04-1.27) Lack of randomised 
studies.  HF not clearly 
defined in included 
23 
studies. 
Wang 
2015 (40) 
8 302,738 AF Observational No 
treatment 
No All-cause mortality 
AF + HF: all-cause mortality 
AF, no HF: all-cause mortality 
HR 1.38 (1.20-1.57) 
HR 1.20 (1.07-1.34) 
HR 1.17 (1.15-1.20) 
Lack of randomised 
studies.  HF not clearly 
defined in included 
studies. 
Hopper 
2014 (29) 
7 2,987 HF in sinus 
rhythm 
RCT Digoxin 
withdrawal 
No Withdrawal of digoxin versus 
 continuation: 
All-cause mortality   
All-cause hospitalisation 
HF hospitalisation 
 
 
RR 1.00 (0.90-1.12) 
RR 1.03 (0.98-1.09) 
RR 1.30 (1.16-1.46) 
Only assesses studies of 
treatment withdrawal in 
chronic HF patients.   
Jaeschke 
1990 (37) 
7 1,072 HF in sinus 
rhythm  
RCT Placebo No Study withdrawal due to worsening 
HF 
 
OR 0.28 (0.16-0.49) 
 
Post-hoc primary 
outcome. 
Sorted by sample size.  AF, atrial fibrillation; CI, confidence interval; HF, heart failure, HR, hazard ratio; N/S, not stated; OR, odds ratio, RCT, 
randomised controlled trial, RR, risk ratio.
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Table 3.  Dosing and indications of cardiac glycosides 
 
 Acute digoxin requirement Chronic digoxin requirement 
Clinical 
indications 
Acute heart rate control in AF Chronic HF symptom control 
Long-term Rate control for AF 
 Digoxin: Total loading dose 0.75-1.5 mg 
over 24 hours in divided doses given 
intravenously or orally. 
Digitoxin: 0.4-0.6 mg intravenous over 
several minutes 
Digoxin: Maintenance dose 0.0625-0.25 mg 
daily (steady state achieved after 7-10 days; 
prolonged with renal impairment). 
Digitoxin: Maintenance dose 0.05-0.3 mg 
daily. 
Loading 
adjustments 
Sensitivity increased by hypokalaemia, hypomagnesaemia, hypercalcemia, hypoxia and 
hypothyroidism.   
Volume of 
distribution 
Distributed widely (lean tissue and muscle) with large volume of distribution (consider 
reduced dose in older patients with low muscle mass; patients <45 kg should receive 50% 
of the normal dose). 
Renal 
impairment 
Reduce loading dose by 1/3 to 1/2 in severe renal insufficiency. 
Concomitant 
medications 
P-glycoprotein efflux transport inhibitors (amiodarone, verapamil) and hydrolysis 
inhibitors (tetracycline, erythromycin) increase serum digoxin concentration. 
P-glycoprotein inducers (dexamethasone, phenytoin, rifampicin) reduce serum digoxin 
concentration. 
Cholestyramine and antacids reduce digoxin absorption by 25% (patients advised to take 
digoxin 2 hours earlier). 
Dose 
adjustment 
Dose and serum digoxin concentration have a linear relationship and dose can be altered in 
proportion to desired concentration (e.g. serum digoxin concentration of 1.6 ng/mL on 
dose 0.25 mg: if desired concentration is 0.8 ng/mL then dose should be reduced by 50% 
to 0.125mg). 
Treatment of 
overdose 
Patients who develop clinically significant manifestations of digoxin poisoning (i.e. life-
threatening arrhythmia, end-organ dysfunction or hyperkalaemia >5.5 mmol/L) should be 
treated with digoxin-specific antibody (Fab) fragments.  If Fab fragments unavailable, 
consider atropine for bradycardia (0.5mg intravenous, repeated as needed) and intravenous 
fluid for hypotension. 
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Figure Legends 
Figure 1.  Mechanisms of Digoxin  
Upper Left: Digoxin augments parasympathetic tone.  Upper right: Digoxin increases the 
refractory period at the atrioventricular node by reducing the gradient of the pacemaker 
potential.  Lower Left: Digoxin inhibits the sodium-potassium ATPase, increasing 
intracellular sodium.  Calcium is prevented from exiting via sodium-calcium exchanger, 
raising intracellular calcium, causing further release of calcium from the sarcoplasmic 
reticulum (calcium-induced calcium-release) leading to a stronger contractile force.  Lower 
right: Frank Starling curves demonstrating the positive inotrope effect. 
 
Figure 2.  The impact of unrecognized bias on treatment effects 
Meta-regression of all-cause mortality according to the risk of bias in all studies providing 
data on rates of death for digoxin versus control (observational and randomized studies).  
Each circle represents a particular study, with the circle size dependent on precision of each 
estimate in a random-effects model.  Reproduced from Ziff et al, BMJ 2015 (2). 
 
Figure 3.  Digoxin and all-cause mortality in observational and randomised studies 
Meta-analyses of all-cause mortality by study design (digoxin versus control therapy).  
Unadjusted analyses use descriptive statistics for the crude mortality rate.  Adjusted analyses 
use baseline adjustment of some known confounding variables.  Propensity-matched analyses 
utilise a propensity score to match patients for a particular set of baseline covariates.  
Randomised trials are placebo-controlled.  HR, hazard ratio; RR, risk ratio.  Adapted from 
Ziff et al, BMJ 2015 (2). 
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Figure 4.  Pros and cons of digoxin therapy 
Key benefits and concerns of digoxin therapy in patients with atrial fibrillation and/or heart 
failure.  
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